# Click Therapeutics, Inc.

> Click Therapeutics develops and commercializes clinically tested software treatments delivered through smartphones. Its portfolio includes Rejoyn, co-developed with Otsuka for depression symptoms, CT-132 for episodic migraine prevention, and Motivista (CT-155) for negative symptoms of schizophrenia. It also develops software designed to enhance specific drugs through its Click SE offering and partners with pharmaceutical and health technology companies.

- **Founded:** 2012
- **Headquarters:** New York, United States
- **Founders:** David Benshoof Klein (Co-founder and CEO), Victor Gao (Co-founder; historically listed as CIO), Bruce Leuchter (Co-founder and founding neuropsychiatrist)
- **Products:** Rejoyn (CT-152), CT-132, Motivista (CT-155), Click SE, AspyreRx assets and CT-181
- **Notable:** Rejoyn received FDA clearance in March 2024 for adjunctive treatment of major depressive disorder symptoms., CT-132 received FDA De Novo authorization on April 11, 2025 for adjunctive episodic migraine prevention., CONVOKE met its primary endpoint for CT-155, announced August 2025.

## Products & services

- **Rejoyn (CT-152)** — Six-week prescription app co-developed with Otsuka, FDA-cleared as an adjunct to clinician-managed outpatient care for depression symptoms in adults 22 and older taking antidepressants. Uses cognitive emotional training and therapeutic lessons. TIME reported an initial $50 out-of-pocket price and planned $200 insurer price in October 2024; these are historical launch prices, not a current quote.
- **CT-132** — FDA De Novo-authorized prescription digital therapeutic for preventive treatment of episodic migraine in adults 18 and older, adjunctive to acute and/or preventive migraine treatments.
- **Motivista (CT-155)** — FDA-cleared July 30, 2026 for negative symptoms of schizophrenia as an adjunct to clinician-managed outpatient care including antipsychotic therapy in adults 18 and older with clinically stable positive symptoms. FDA record supersedes older investigational descriptions; launch availability is not established here.
- **Click SE** — Development offering for software-enhanced drugs: software designed and clinically validated to provide added benefit with a specific medication.
- **AspyreRx assets and CT-181** — Acquired Better Therapeutics assets include FDA-authorized type 2 diabetes software AspyreRx. Click announced adaptation work for obesity and drug combinations, including GLP-1s, rather than self-commercialization of AspyreRx as-is. CT-181 remains a development candidate.
- **Clickotine** — Smoking-cessation app evaluated in an early 416-person, eight-week single-arm study. Publication reports self-reported abstinence, not randomized proof of efficacy; current commercial availability not confirmed.
- **Migraine PowerPlug collaboration** — Ultrahuman wellness and educational feature under development using CT-132 technology and wearable biometrics. It is not a prescription digital therapeutic or a disease-treatment product.

## Achievements

- Rejoyn received FDA clearance in March 2024 for adjunctive treatment of major depressive disorder symptoms.
- CT-132 received FDA De Novo authorization on April 11, 2025 for adjunctive episodic migraine prevention.
- CONVOKE met its primary endpoint for CT-155, announced August 2025.
- Motivista (CT-155) received FDA 510(k) clearance July 30, 2026.
- April 2026 financing announcement reported 63 granted patents.

## Latest updates

- **2026-07** — FDA cleared Motivista (CT-155), K254038, on July 30 for negative symptoms of schizophrenia under its specified adjunctive indication.
- **2026-04** — Boehringer invested $50 million in Series D and transferred full CT-155 product responsibility to Click; additional dedicated commercial funding was not quantified.
- **2026-04** — Behavioral Health Business reported 27% workforce cuts; management described retooling for commercialization.
- **2026-01** — Ultrahuman partnership announced Migraine PowerPlug development as a wellness feature.

## Links

- Website: https://www.clicktherapeutics.com
- LinkedIn: https://www.linkedin.com/company/click-therapeutics-inc-/
- Twitter/X: https://twitter.com/clickthera
- Instagram: https://www.instagram.com/click_tx/
- Facebook: https://facebook.com/ClickTherapeutics

---

Profile page: https://yespress.io/click-therapeutics-inc
Published by YesPress — https://yespress.io
Last updated: 2026-10-03